# Completeness Review: AIMedicalDeviceComplianceManager

- **Review date:** 2026-07-18
- **Assessment basis:** Static source and configuration inspection only. Dependencies were not installed, and no build, database migration, external integration, or runtime workflow was executed.

## Classification

**Functional but incomplete**

## Verdict

This is a substantive but unfinished clinical/health application: 79 project-owned source files and 2 manifest(s) expose a coherent surface, but the source does not demonstrate a production-complete AIMedical Device Compliance Manager workflow.

## Why it is not complete

- 27 files are explicitly named as gap/backlog surfaces, so page and route counts overstate implemented product capability.
- 17 project-owned files contain direct provider/chat-completion markers; generic model calls are not a substitute for typed domain tools, grounded evidence, deterministic rules, or evaluations.
- 40 files contain mock, sample, placeholder, simulated, or random-data signals, leaving important outcomes disconnected from authoritative systems.
- No recognizable project-owned automated tests were found for the primary workflow.
- No checked-in CI workflow was found to continuously verify builds, tests, migrations, and security checks.
- No environment example/template was found, leaving required configuration and secret boundaries undocumented.

## Needed features

1. Model devices, intended use, classifications, markets, design controls, requirements, risks, verification/validation evidence, submissions, and post-market changes as versioned records.
2. Add traceability from user needs through hazards, controls, requirements, tests, deviations, CAPA, and released device/software versions.
3. Integrate controlled document/QMS, complaint, supplier, cybersecurity/SBOM, test-lab, and regulatory-submission systems with signed approvals.
4. Implement jurisdiction and effective-date aware checks for FDA/EU MDR/IVDR and applicable quality/risk/software standards, backed by authoritative citations.
5. Require qualified regulatory review, segregation of duties, electronic-signature controls, immutable audit, retention, and exportable submission evidence.
6. Test change impact, missing evidence, conflicting revisions, recalls, cybersecurity updates, and submission-package reproducibility in CI.

## Implementation progress

1. **Implemented locally:** governed device-change cases version intended use/classification, traceability/risk/V&V/submission evidence, qualified approval, releases, post-market changes, recall review, and close with effective dates and retention.
2. **Implemented locally:** controlled evidence kinds trace user needs, requirements, hazards, controls, risk files, tests, deviations/CAPA, SBOM/cybersecurity, supplier/complaint records, submission manifests, signatures, and recalls; immutable digests and optimistic versions expose conflicts.
3. **Durable boundary implemented; external gate remains:** eQMS/documents, complaints, suppliers, SBOM/cybersecurity, labs, and submissions are declared unconfigured and receipt-only. Credentials, signed approvals, system validation, and authoritative records fail closed.
4. **Implemented locally as an administrative gate:** deterministic checks bind market, jurisdiction rule version/effective date, traceability coverage, risk/device versions, and V&V status. No citation or regulatory decision is fabricated; authoritative sources and qualified interpretation remain required.
5. **Implemented locally:** manufacturer/subject isolation, quality/regulatory/risk/independent roles, dual control, immutable audit/evidence, retention, electronic-signature evidence, secure configuration, and explicit non-regulatory/non-clinical boundaries are enforced.
6. **Implemented locally where data-independent:** tests and CI cover missing evidence, incomplete traceability, conflicting versions, role/dual-control boundaries, recall-capable transitions, migration immutability, provider quarantine, and package evidence. Validated QMS/lab/cybersecurity/submission fixtures remain external gates.

## Risks or launch blockers

- Incorrect or unreviewed output can cause patient harm.
- Health data requires strong privacy, access, retention, and audit controls.
- The root launcher can terminate unrelated processes occupying configured ports.
- The root launcher seeds, creates, migrates, or otherwise mutates database state during startup.
- The root launcher installs dependencies at run time, reducing reproducibility and expanding supply-chain risk.

## Evidence inspected

- `client/package.json` — inspected project-owned structure or implementation evidence.
- `client/src/App.jsx` — inspected project-owned structure or implementation evidence.
- `client/src/pages/GapAgentic.jsx` — inspected project-owned structure or implementation evidence.
- `start.sh` — inspected project-owned structure or implementation evidence.
- `server/schema.sql` — inspected project-owned structure or implementation evidence.
- `client/src/components/Pagination.jsx` — inspected project-owned structure or implementation evidence.

## Recommended next action

Choose one production clinical/health journey, connect its authoritative systems, define measurable acceptance tests, and close its data, permission, failure, and operational gaps before adding screens.
